<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Biostatistics</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BA89ED91-4884-4786-B5F7-E9A89A00FD24"><gtr:id>BA89ED91-4884-4786-B5F7-E9A89A00FD24</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Donegan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK021435%2F1"><gtr:id>29B1D2B9-A698-4B84-A900-E0DBAB464FD6</gtr:id><gtr:title>Explaining inconsistency in evidence synthesis.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K021435/1</gtr:grantReference><gtr:abstractText>What is the research area?
Healthcare decision makers use clinical research findings to decide on the best treatment for patients. Systematic reviews of clinical trials are the best type of research to use to make these decisions. In brief, a systematic review is a document that summarises similar studies in an unbiased way.

Most reviews use a statistical technique called meta-analysis. When only two treatments exist for the same condition, results from trials that compare the two treatments are combined together using conventional meta-analysis, to get a pooled average result. The average result tells us whether one treatment is better than the other treatment, and how much better.

However, when many treatments exist for the same condition, network meta-analysis (NMA) can be used. Results from trials that compare any of the treatments are combined together using NMA to get a set of results. The set of results tell us how each treatment compares to each other treatment.

An assumption called homogeneity applies when conventional meta-analysis is used. An assumption termed consistency is made when using NMA. If an assumption is not satisfied, the results of the meta-analysis and any clinical decisions based on them will be invalid.

Methods to assess homogeneity are well established. If the homogeneity assumption is invalid, there is said to be heterogeneity. Heterogeneity may be explained using existing approaches so that valid results are produced.

Methods to assess consistency have been proposed by experts but are not widely used in reviews. If the consistency assumption is invalid, there is inconsistency. There is currently only one complex approach to evaluate whether inconsistency is explained. In inconsistency is explained, valid results are produced; whereas, the results will be invalid if the causes of inconsistency is undetermined.

Before a process for explaining inconsistency is promoted, various issues should be investigated to improve its usefulness:
1. How should review authors choose potential causes of the inconsistency?
2. Should review authors use the trials' raw data or results from trial reports?
3. Should review authors use at least some trials' raw data rather than no raw data?
4. How should review authors evaluate whether inconsistency is explained?

What is the aim?
The aim is to develop and promote a process for explaining inconsistency in NMA.

Why is this research important?
NMA is a relatively new method that is increasingly being used. There is uncertainty regarding how to best assess consistency, and what to do if inconsistency is detected. The proposed research will contribute important knowledge with regard to such issues.

Vitally, research has shown that the quality of published NMAs is poor. Sometimes, the results of the NMA are presented when the assumption is invalid. Therefore, clinical decisions could be made based on misleading results. If a process for explaining inconsistency was developed and promoted, as proposed here, the quality of NMAs should improve, and the reported results would be appropriate for making healthcare decisions.

Furthermore, NMA can be used whenever many treatments exist for the same condition; therefore, NMA is probably applicable to all conditions and, could potentially affect many healthcare decisions.

How will the aim be achieved?
There are six research components: (A) establish how and when heterogeneity is explained in practice; (B) explore how best to choose potential causes of inconsistency; (C-D) explore when it is valuable to collect raw data from trial investigators and when it is best to use data from trial reports; (E) explore new approaches to decide whether inconsistency has been explained; (F) tailor and promote the process.

A collaboration will be formed between methodologists and researchers involved in preparing reviews, to ensure that the research is of high quality, disseminated effectively, and is useful.</gtr:abstractText><gtr:technicalSummary>Background
Network meta-analysis (NMA) compares many treatments in a single analysis while using direct and indirect evidence. The consistency assumption underlies NMA. If inconsistency exists, the results of the NMA will be invalid, but causes of the inconsistency can be sought by including treatment by covariate interactions in the NMA model. If the inconsistency is eliminated when interactions are included, the results of the model with interactions could be used to draw suitable conclusions. In practice, there is uncertainty regarding what to do if inconsistency is detected, and the quality of published NMAs is poor. If a process for explaining inconsistency was developed and promoted, the quality of NMAs should improve, and the results would be valid and appropriate for making healthcare decisions.

Aim
The aim is to develop and promote a process for explaining inconsistency in NMA.

Methods
A review will be carried out to establish how interactions are explored in reviews. Existing approaches for choosing covariates will be compared with new approaches through application to reviews. Two simulation studies will be carried out which aim to compare NMA models including interactions based on individual patient data (IPD) (i.e. raw data) with models based on aggregate data from trial reports, and determine how the results of NMA are affected as the proportion of IPD increases. Simpler, new approaches to evaluate whether interactions explain inconsistency will be compared with an existing approach through application to reviews. A process for explaining inconsistency will be tailored and demonstrated through application to reviews.

Opportunities
Results may be reported in review updates. Collected IPD will be valuable for future methodological projects. The review will provide the chance to give guidance regarding how the exploration of interactions can be improved. The research will inform future endeavours to promote the process on a larger scale.</gtr:technicalSummary><gtr:potentialImpactText>Who are the potential non-academic beneficiaries of the research? 
The non-academic beneficiaries of this research could be located globally and include healthcare decision makers who use reviews to formulate treatment guidelines, the NHS, heath care providers who use treatment guidelines, patients, and the patients' contacts including dependants.
 
How might they benefit from the research?
1. Healthcare decision makers have access to high quality NMAs. 
If review authors are better equipped to do NMA, the number of high quality NMAs may increase. It is easier for a healthcare decision maker to decide on the best treatment option when presented with the results of an NMA, rather than many conventional meta-analyses, because the relative effects of all available treatments are estimated even when two treatments have not been directly compared. More importantly, healthcare decisions should be more reliable because published NMAs use suitable methods and report valid results. 
 
2. Healthcare decision makers have access to high quality reviews with respect to treatment by covariate interactions. 
If review authors are better equipped to explore interactions, review authors are more likely to detect interactions if they exist, and report valid, clear results. By reading such review, healthcare decision makers will benefit from gaining a fuller understanding of the relative effects of treatments in different patient groups. If results are reported clearly in the reviews, healthcare decision makers will find it easier to decide which is the best treatment for different patient populations. Furthermore, if appropriate methods are used and valid results are reported, healthcare decisions should be more reliable. 
 
3. The NHS and healthcare providers may provide better patient care and reduce costs. 
Improved healthcare decisions and treatment guidelines will benefit the NHS and healthcare providers because the most suitable treatments are being prescribed to patients. Costs may be reduced if patients are prescribed more beneficial treatments because visits and treatment changes will reduce. 
 
4. Improved health and well-being of patients. 
The well-being of patients should improve if they are prescribed treatments that are more beneficial for them. This improvement is a realistic impact, because identification of interactions in reviews will inform healthcare decision makers whether different treatments are better for different patients groups. For some clinical indications, a change in treatment could make a substantial difference to patients' health. Improvements in health could potentially have further important impacts on patients' lifestyles (e.g. financial implications, and employment).
 
5. Positive emotional and practical impacts on the patients' contacts including dependants. 
Negative emotional and practical impacts on patients' contacts will lessen if the patients' well-being is improved. The impact for particular individuals will vary, for example, depending on the severity of the patient's condition. 
 
When might they benefit from the research? 
The proposed research will be available online, but non-academics will not be targeted in terms of dissemination. 
 
Healthcare decision makers and heath care providers affiliated with Cochrane Review Groups in Liverpool or LRiG will benefit during the fellowship if they receive an evidence update and are invited to demonstrations of the proposed methodology. See 'Communications Plan' for details. 
 
The timing of benefits to other beneficiaries will partly depend on the rate of uptake of the methods by review authors, when the treatment guidelines are updated, and how long possible treatment changes will take to have an impact on the patients' health.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>359237</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences</gtr:department><gtr:description>University of Bristol and University of Liverpool</gtr:description><gtr:id>DA397B20-F6DC-4781-BEFA-4ECBA2C49152</gtr:id><gtr:impact>One published article: Donegan S, Williams L, Dias S, Tudur-Smith C, Welton N. Exploring Treatment by Covariate Interactions Using Subgroup Analysis and Meta-Regression in Cochrane Reviews: A Review of Recent Practice. PLoS ONE 2015 10(6): e0128804. DOI: 10.1371/journal.pone.0128804 

Two articles currently submitted to research synthesis methods (and further articles in preparation): 
1. Donegan S, Dias S, Tudur-Smith C, D'Alessandro U, Welton N. Network meta-analysis including treatment by covariate interactions: can there be consistency at one covariate value and inconsistency at another covariate value?
2. Donegan S, Dias S, Tudur-Smith C, Marinho V, Welton N. Graphs of study contributions and covariate distributions for network meta-regression.

Presentations:
2016 'Subgroup analyses in Cochrane reviews and network meta-analysis' (University of Manchester).
2016 'Explaining inconsistency in network meta-analysis' (University of Bristol).
2015 'Network meta-analysis using aggregate data and individual-patient data' (Inserm course, Bordeaux, France).
2014 'Exploring treatment by covariate interaction: recent practice' (Cochrane Colloquium, India). 
2014 'Review of interaction analyses in systematic reviews' (University of Liverpool).
2013 'The value of individual patient data for network meta-analysis' (Royal Statistical Society, London).
2013 'Overview of methods for assessing consistency' (Cochrane Comparing Multiple Interventions Methods Group meeting , University of Bristol). 
2013 'Review of interaction analyses' (the biennial editors' meeting of the Cochrane Infectious Diseases Group, University of Liverpool).</gtr:impact><gtr:outcomeId>58c2a887484340.87277762-1</gtr:outcomeId><gtr:partnerContribution>They have met with me regularly and commented on articles for publication.</gtr:partnerContribution><gtr:piContribution>Collaborating on several methodological research project. I have met with Nicky Welton and Sofia Dias regularly to discuss the research. I have written articles regarding the research and disseminated the research through presentations.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Dentistry</gtr:department><gtr:description>Valeria Marinho</gtr:description><gtr:id>40DE7C70-296D-464C-80B8-1241D9171E84</gtr:id><gtr:impact>One article that is currently submitted to research synthesis methods ('Graphs of study contributions and covariate distributions for network meta-regression.'). The methods in the article will also be presented at a meeting in June.</gtr:impact><gtr:outcomeId>58c2be8b8e4db7.55675255-1</gtr:outcomeId><gtr:partnerContribution>Valeria supplied a dataset and commented on the finished article.</gtr:partnerContribution><gtr:piContribution>I have collaborated with Valeria Marinho on a methodological project. I invented new methods and Valeria supplied a dataset to demonstrate the methods in an article. I wrote the article.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Individual patient dataset of treatments for uncomplicated malaria for network meta-analysis.</gtr:description><gtr:id>D9AA1D61-8BD8-4525-AEEA-BB68E2DCE014</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58c2c135899a63.35262372</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Uncomplicated malaria dataset.</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Aggregate dataset of trials of severe malaria for network meta-analysis.</gtr:description><gtr:id>3E8EBA56-10DE-4D01-8378-234CB0EF0777</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c2c0fb69e476.02682905</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Severe malaria dataset</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>New inconsistency models have been developed to analyse individual patient data and include treatment by covariate interactions. This work is under development but will be provided to other research groups shortly.</gtr:description><gtr:id>915F12D4-39C3-4930-B102-B6E7539972F0</gtr:id><gtr:impact>Too early for impacts.</gtr:impact><gtr:outcomeId>58c2c0aa3719a0.50521045</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Extension of inconsistency models to individual patient data and covariate interactions.</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Various nodes-splitting models have been developed to analyse individual patient data and include treatment by covariate interactions.</gtr:description><gtr:id>953A0D85-F11E-47B6-B34E-C8C1C70A4404</gtr:id><gtr:impact>Too early to notice impacts.</gtr:impact><gtr:outcomeId>58c2c03ac14b70.91727741</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Extension of node-spltting models to individual patient data and covariate interactions</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Aggregate dataset of cholera treatments for network meta-analysis.</gtr:description><gtr:id>801A09AF-9A8D-4BFC-A3EF-4D6421FF16F1</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58c2c1c23c5fc0.75373239</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cholera dataset</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9CD53EFF-396E-4F22-B362-B8061C971827</gtr:id><gtr:title>Cochrane Database of Systematic Reviews - Protocols</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f745b3a2928d9b889e6666145813b1ee"><gtr:id>f745b3a2928d9b889e6666145813b1ee</gtr:id><gtr:otherNames>Theron G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:outcomeId>58c2a547492585.18021838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46E936E2-BF32-43D3-AB65-8FDF8E3CE8A9</gtr:id><gtr:title>A systematic review of placebo-controlled trials of topiramate: How useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug?</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5fd3df21484b6f6203c5ef10c4edc32"><gtr:id>a5fd3df21484b6f6203c5ef10c4edc32</gtr:id><gtr:otherNames>Donegan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>56d6cb11a7bd06.33279849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC439A2D-A4B3-4CB5-8D1E-207C4DE76A24</gtr:id><gtr:title>Assessing key assumptions of network meta-analysis: a review of methods.</gtr:title><gtr:parentPublicationTitle>Research synthesis methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5fd3df21484b6f6203c5ef10c4edc32"><gtr:id>a5fd3df21484b6f6203c5ef10c4edc32</gtr:id><gtr:otherNames>Donegan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-2879</gtr:issn><gtr:outcomeId>54625224e90685.11067057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70D4EC07-8A01-460E-A337-9FCCAA3CBABE</gtr:id><gtr:title>Rapid diagnostic tests versus clinical diagnosis for managing people with fever in malaria endemic settings.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8ad812800bde758562c127aa6f310ec"><gtr:id>f8ad812800bde758562c127aa6f310ec</gtr:id><gtr:otherNames>Odaga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>58c2a223a9c544.64449518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE12FCFE-BEB1-4EBA-A693-AADF79CA1C6C</gtr:id><gtr:title>Exploring treatment by covariate interactions using subgroup analysis and meta-regression in cochrane reviews: a review of recent practice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5fd3df21484b6f6203c5ef10c4edc32"><gtr:id>a5fd3df21484b6f6203c5ef10c4edc32</gtr:id><gtr:otherNames>Donegan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d6cb11d751a2.14167706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C876F237-BDBF-4730-A475-6E9BEAEDB2B1</gtr:id><gtr:title>The diagnostic accuracy of the GenoType(&amp;reg;) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f745b3a2928d9b889e6666145813b1ee"><gtr:id>f745b3a2928d9b889e6666145813b1ee</gtr:id><gtr:otherNames>Theron G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>54624f700f9f12.40748272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F4288C2-42A6-4418-A38C-9788AA88944F</gtr:id><gtr:title>The impact of pyrethroid resistance on the efficacy of insecticide-treated bed nets against African anopheline mosquitoes: systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e389f054b36a64f78b4bd770de17e7e"><gtr:id>7e389f054b36a64f78b4bd770de17e7e</gtr:id><gtr:otherNames>Strode C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>54625153ecf1f2.70800786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BD48E45-8BA4-49DA-A426-1ECD33624667</gtr:id><gtr:title>Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5696437e17c06e102c1cea4b53f54fe4"><gtr:id>5696437e17c06e102c1cea4b53f54fe4</gtr:id><gtr:otherNames>Bowman LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>58c2a1e612fd62.76189983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C99011B3-FEE7-495A-B8FA-FC1B254E1E80</gtr:id><gtr:title>Graphs of study contributions and covariate distributions for network meta-regression.</gtr:title><gtr:parentPublicationTitle>Research synthesis methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5fd3df21484b6f6203c5ef10c4edc32"><gtr:id>a5fd3df21484b6f6203c5ef10c4edc32</gtr:id><gtr:otherNames>Donegan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1759-2879</gtr:issn><gtr:outcomeId>5a995f1b2b82f6.14041291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4F9B75E-9E9D-4556-9C10-85E8D25DA670</gtr:id><gtr:title>Treatment outcome after failure of a first antiepileptic drug.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98f47ea97497d37864b4cacd71d1aced"><gtr:id>98f47ea97497d37864b4cacd71d1aced</gtr:id><gtr:otherNames>Bonnett LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>54625028e450d8.37618919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB46E7AE-5234-40DE-A75D-A7808C5A2738</gtr:id><gtr:title>Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7de5ac7c13fb67e56cf53e28aab91ba"><gtr:id>e7de5ac7c13fb67e56cf53e28aab91ba</gtr:id><gtr:otherNames>Zani B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>546251b5ccac36.15471731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F149E9A-BAD1-4C68-9EFA-4B7A54C9D1B5</gtr:id><gtr:title>Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7209d4e36798da17d68ffb47ef531d0"><gtr:id>f7209d4e36798da17d68ffb47ef531d0</gtr:id><gtr:otherNames>Taylor-Robinson DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>56d6cb12345367.96600045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1896E3B8-306F-4DEC-8F33-6C5AF45269EC</gtr:id><gtr:title>Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1681cbb3eb974dd9a78b6cdba6eac10"><gtr:id>d1681cbb3eb974dd9a78b6cdba6eac10</gtr:id><gtr:otherNames>Abba K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>56d6cb120dec26.94762738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC1382B2-6EBB-4FC1-AADD-9631EF3D5B9E</gtr:id><gtr:title>Network meta-analysis including treatment by covariate interactions: Consistency can vary across covariate values.</gtr:title><gtr:parentPublicationTitle>Research synthesis methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5fd3df21484b6f6203c5ef10c4edc32"><gtr:id>a5fd3df21484b6f6203c5ef10c4edc32</gtr:id><gtr:otherNames>Donegan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-2879</gtr:issn><gtr:outcomeId>5a2fdaf59f3a66.31292951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>612D9F9C-2B12-46FD-AB35-D84C71CAE10D</gtr:id><gtr:title>Cluster Randomised Trials in Cochrane Reviews: Evaluation of Methodological and Reporting Practice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e426919b4f7227cb5a8f53d16e252b6"><gtr:id>2e426919b4f7227cb5a8f53d16e252b6</gtr:id><gtr:otherNames>Richardson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d51cc1c3c77.95475902</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K021435/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>B7F5A9CA-62C7-4E68-A2B2-3D6CCA85E16B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>7.3  Management and decision making</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>